Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

MAXIDEX Eye drops, suspension (2020)

Αναφορές

Βιβλιογραφική αναφορά

Στοιχεία εκδότη

Εκδότης Novartis Pharmaceuticals UK Limited
Διεύθυνση 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

MAXIDEX 0.1% w/v, eye drops, suspension.

Qualitative and quantitative composition

Dexamethasone 0.1% w/v. <u>Excipient with known effect in suspension:</u> Benzalkonium Chloride 0.01% w/v. For the full list excipients, see section 6.1.

Pharmaceutical form

Eye drops, suspension.

Therapeutic indications

Indicated for treatment of steroid responsive inflammatory conditions of the conjunctiva, cornea and anterior segment of the eye, such as, anterior uveitis, iritis, cyclitis, allergic and vernal conjunctivitis, ...

Posology and method of administration

Adults, adolescents, and children (2 years of age and above) The frequency of instillation of drops and the duration of treatment will vary depending upon the severity of the underlying condition and the ...

Contraindications

Vaccinia, varicella, or other viral diseases of cornea and conjunctiva (except herpes zoster keratitis). Herpes simplex keratitis. Fungal diseases of ocular structures or untreated parasitic eye infections. ...

Special warnings and precautions for use

Prolonged use of topical ophthalmic corticosteroids may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, reduced visual acuity, visual field defects and posterior subcapsular ...

Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. Concomitant use of topical steroids and topical NSAIDs may increase the potential for corneal healing problems. CYP3A4 inhibitors (including ritonavir and cobicistat): ...

Pregnancy and lactation

Fertility Studies have not been performed to evaluate the effect of topical ocular administration of dexamethasone on fertility. There is limited clinical data to evaluate the effect of dexamethasone on ...

Effects on ability to drive and use machines

MAXIDEX has no or negligible influence on the ability to drive and use machines. As with any topical ophthalmic medicinal product, temporary blurred vision or other visual disturbances may affect the ability ...

Undesirable effects

Summary of the safety profile In clinical trials, the most common adverse reaction was ocular discomfort. Tabulated list of adverse reactions The following adverse reactions are classified according to ...

Overdose

Long-term intensive topical use may lead to systemic effects. Oral ingestion of the contents of the bottle (up to 10 mls) is unlikely to lead to any serious adverse effects. An ocular overdose of Maxidex ...

Pharmacodynamic properties

<b>Pharmacotherapeutic Group:</b> Ophthalmologicals: Anti-inflammatory Agents <b>ATC Code:</b> S01BA01 Dexamethasone has been demonstrated by animal and human studies based on oral application to possess ...

Pharmacokinetic properties

Dexamethasone is absorbed rapidly after oral administration with a half-life of about 190 minutes. Sufficient absorption may occur after topical application to the skin and eye to produce systemic effects. ...

Preclinical safety data

Repeat dose topical ocular safety studies with dexamethasone in rabbits have shown systemic corticosteroid effects. Such effects are considered to be unlikely when MAXIDEX is used as recommended. Dexamethasone ...

List of excipients

Sodium phosphate Polysorbate 80 Disodium edetate Sodium chloride Benzalkonium chloride Hypromellose Citric acid Purified water

Incompatibilities

None known.

Shelf life

20 months (unopened), 1 month (after first opening).

Special precautions for storage

Do not store above 25°C. Do not refrigerate or freeze. Keep container tightly closed. Discard 1 month after first opening. Store in the original package.

Nature and contents of container

Drop-Tainer 5ml and 10ml Natural Low Density Polyethylene Bottles and Plugs. Polystyrene or Polypropylene cap.

Special precautions for disposal and other handling

Do not touch dropper tip to any surface as this may contaminate the contents. If the drop of medication is not retained in the eye upon dosing for any reason then instill another drop.

Marketing authorization holder

Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom

Marketing authorization number(s)

PL 00101/0999

Date of first authorization / renewal of the authorization

28/09/1990 / 17/09/2003

Date of revision of the text

03 September 2020

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.